Rationale for therapeutic decision-making in locally advanced and metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer, starting from a clinical case
Abstract
Keywords
Full Text:
PDFReferences
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016; 26(1):1-133. https://doi.org/10.1089/thy.2015.0020
Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet. 2002; 360(9340):1131-1135. https://doi.org/10.1016/S0140-6736(02)11199-8
Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006; 91(8):2892-2899. https://doi.org/10.1210/jc.2005-2838
Henriques de Figueiredo B, Godbert Y, Soubeyran I, et al. Brain metastases from thyroid carcinoma: a retrospective study of 21 patients. Thyroid. 2014; 24(2):270-276. https://doi.org/10.1089/thy.2013.0061
Jayarangaiah A, Sidhu G, Brown J, et al. Therapeutic options for advanced thyroid cancer. Int J Clin Endocrinol Metab. 2019; 5(1):26-34. https://doi.org/10.17352/ijcem.000040
Stewart KE, Strachan MWJ, Srinivasan D, MacNeill M, Wall L, Nixon IJ. Tyrosine kinase inhibitor therapy in locally advanced differentiated thyroid cancer: a case report. Eur Thyroid J. 2019; 8(2):102-107. https://doi.org/10.1159/000494880
Szumowski P, Abdelrazek S, Iwanicka D, et al. Dosimetry during adjuvant 131I therapy in patients with differentiated thyroid cancer-clinical implications. Sci Rep. 2021; 11(1):13930. https://doi.org/10.1038/s41598-021-93431-1
Iñiguez-Ariza NM, Bible KC, Clarke BL. Bone metastases in thyroid cancer. J Bone Oncol. 2020; 21:100282. https://doi.org/10.1016/j.jbo.2020.100282
Dinneen SF, Valimaki MJ, Bergstralh EJ, Goellner JR, Gorman CA, Hay ID. Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab. 1995; 80(7):2041-2045. https://doi.org/10.1210/jcem.80.7.7608252
Ikekubo K, Hino M, Ito H, et al. Seven cases of brain metastasis from papillary thyroid carcinoma. Kaku Igaku. 2000; 37(4):349-357.
Tahmasebi FC, Farmer P, Powell SZ, et al. Brain metastases from papillary thyroid carcinomas. Virchows Arch. 2013; 462(4):473-480. https://doi.org/10.1007/s00428-013-1394-4
Osborne JR, Kondraciuk JD, Rice SL, et al. Thyroid cancer brain metastasis: survival and genomic characteristics of a large tertiary care cohort. Clin Nucl Med. 2019; 44(7):544-549. https://doi.org/10.1097/RLU.0000000000002618
Saito F, Uruno T, Shibuya H, et al. Prognosis after brain metastasis from differentiated thyroid carcinoma. World J Surg. 2016; 40(3):574-81. https://doi.org/10.1007/s00268-016-3405-5
Hirsch D, Gorshtein A, Robenshtok E, et al. Second radioiodine treatment: limited benefit for differentiated thyroid cancer with locoregional persistent disease. J Clin Endocrinol Metab. 2018; 103(2):469-476. https://doi.org/10.1210/jc.2017-01790
Fullmer T, Cabanillas ME, Zafereo M. Novel therapeutics in radioactive iodine-resistant thyroid cancer. Front Endocrinol (Lausanne). 2021; 12:720723. https://doi.org/10.3389/fendo.2021.720723
Borrelli N, Panebianco F, Condello V, et al. Characterization of activating mutations of the MEK1 gene in papillary thyroid carcinomas. Thyroid. 2019; 29(9):1279-1285. https://doi.org/10.1089/thy.2019.0065
Seo GH, Cho YY, Chung JH, Kim SW. Increased risk of leukemia after radioactive iodine therapy in patients with thyroid cancer: a nationwide, population-based study in Korea. Thyroid. 2015; 25(8):927-934. https://doi.org/10.1089/thy.2014.0557
Alsaud A, Mohamed S, Yassin MA, Ashour A, Obeidat K, Azrieh B. Acute myeloid leukemia after low-dose radioiodine therapy for papillary thyroid carcinoma. Case Rep Oncol. 2020; 13(1):207-211. https://doi.org/10.1159/000505686
Chakravarty D, Santos E, Ryder M, et al. Small- molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest. 2011; 121(12):4700-4711. https://doi.org/10.1172/JCI46382
Zhang Z, Liu D, Murugan AK, Liu Z, Xing M. Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer. Endocr Relat Cancer. 2014; 21(2):161–173. https://doi.org/10.1530/ERC-13- 0399
Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014; 384(9940):319-328. https://doi.org/10.1016/S0140-6736(14)60421-9
Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015; 372:621-630 https://doi.org/10.1056/NEJMoa1406470
Pitoia F, Jerkovich F. Selective use of Sorafenib in the treatment of thyroid cancer. Drug Des Devel Ther. 2016; 10:1119–1131. https://doi.org/10.2147/DDDT. S82972
Cabanillas ME, de Souza JA, Geyer S, et al. Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer: results of a multicenter phase II international thyroid oncology group trial. J Clin Oncol. 2017; 35(29):3315–3321. https://doi.org/10.1200/JCO.2017.73.0226
Cohen EE, Tortorici M, Kim S, Ingrosso A, Pithavala YK, Bycott P. A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/ pharmacodynamic analyses. Cancer Chemother Pharmacol. 2014; 74(6):1261–1270. https://doi.org/10.1007/s00280-014-2604-8
Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 2010; 11(10):962–972. https://doi.org/10.1016/S1470-2045(10)70203-5
Yansong L, Yang H, Ding Y, et al. Donafenib in progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer: results of a randomized, multicenter, phase II trial. Thyroid. 2020; 31(4):607-615. https://doi.org/10.1089/thy.2020.0235
Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW. Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer. Clin Cancer Res. 2011; 17(20):6482–6489. https://doi.org/10.1158/1078-0432.ccr-11-0933
Tsumagari K, Abd Elmageed ZY, Sholl AB, et al. Bortezomib sensitizes thyroid cancer to BRAF inhibitor in vitro and in vivo. Endocr Relat Cancer. 2017; 25(1):99–109. https://doi.org/10.1530/erc-17-0182
Kebebew E, Ghosh C, Kumar S, et al. A combinatorial strategy for targeting BRAF V600E mutant cancers with BRAF V600E inhibitor (PLX4720) and tyrosine kinase inhibitor (ponatinib). Clin Cancer Res. 2020; 26:2022-2036. https://doi.org/10.1158/1078-0432.ccr-19-1606
Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013; 368(7):623–632. https://doi.org/10.1056/nejmoa1209288
Rothenberg SM, McFadden DG, Palmer EL, Daniels GH, Wirth LJ. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res. 2014; 21(5):1028–1035. https://doi.org/10.1158/1078-0432.ccr-14-2915
Dunn LA, Sherman EJ. Baxi SS, et al. J Clin Endocrinol Metab. 2019; 104(5):1417-1428. https://doi.org/10.1210/jc.2018-01478
Jaber T, Waguespack SG, Cabanillas ME, et al. Targeted therapy in advanced thyroid cancer to resensitize tumors to radioactive iodine. J Clin Endocrinol Metab. 2018; 103(10): 3698–3705. https://doi.org/10.1210/jc.2018-00612
DOI: http://dx.doi.org/10.22551/2021.33.0804.10190
Copyright (c) 2021 Cristina Alina Silaghi, Oana Stãnoiu-Pînzariu, Horaţiu Silaghi, Doina Piciu, Carmen Emanuela Georgescu
Archive of Clinical Cases is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
ISSN: 2360-6975